Danish researchers found millions of people stop taking Ozempic, Wegovy, and similar medications within a year.
The team analysed data from over 77,000 adults without diabetes who used anti-obesity medications. They discovered 52 percent quit within 12 months. Eighteen percent stopped within three months, 31 percent within six months, and 42 percent after nine months.
GLP-1 Drugs Require Consistent Use
Ozempic and Wegovy mimic hormones that reduce appetite. Researchers stress these drugs need long-term use to work effectively.
Professor Reimar W. Thomsen said, “Patients lose all appetite control benefits if they stop taking these medications.”
Risk Factors for Stopping
Younger adults under 30 stopped 48 percent more often than people aged 45 to 59. People in low-income areas quit 14 percent more often than those in affluent neighborhoods. Men also left treatment more frequently than women.
Researchers noted patients who used gastrointestinal or psychiatric medications may have stopped due to nausea or vomiting. Chronic health conditions also increased dropout rates.
Cost Limits Access
A month of Ozempic in Denmark costs up to €313 without diabetes coverage, compared to €120 in Germany. High costs likely contribute to early discontinuation.
Health Implications of Stopping
Stopping these drugs often leads to regained weight. Researchers highlight that consistent use can lower risks of heart disease, cancer, and addiction.
Thomsen emphasized, “Supporting patients who benefit from these medications is crucial for public health.” He added that understanding who struggles with adherence can improve treatment effectiveness and quality of life.
Future Steps and Research
The study will appear at the European Association for the Study of Diabetes annual meeting in Vienna. Researchers hope the findings guide policies to help patients stay on medication longer.
“With over half of European adults overweight or obese, encouraging adherence is essential to improve health outcomes and extend the benefits of treatment,” Thomsen said.
